表紙
市場調査レポート

EpiCast Report:痛風の疫学的予測

EpiCast Report: Gout - Epidemiology Forecast to 2023

発行 GlobalData 商品コード 300492
出版日 ページ情報 英文 55 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.12円で換算しております。
Back to Top
EpiCast Report:痛風の疫学的予測 EpiCast Report: Gout - Epidemiology Forecast to 2023
出版日: 2014年04月24日 ページ情報: 英文 55 Pages
概要

通風は炎症性関節炎の一種で、関節内部での尿酸の結晶化が引き金となって発症します。また高尿酸血症とも関連しています。世界の主要6ヶ国における痛風の発症者数は、2013年の1,374,065人から、2023年には1,649,065人まで増加する(年平均成長率(CAGR)は2.00%)と予測されています。また、診断を受けた有病者数も、2013年の13,750,047人から、2023年には17,625,944人まで増加する(年平均成長率(CAGR)は2.82%)と推計されています。

当レポートでは、世界の主要6ヶ国(米国・フランス・ドイツ・イタリア・スペイン・英国)における痛風の発症状況や今後の見通しについて分析し、疾患の特徴(リスク要因や主な共存症など)や世界各国での動向、現在の有病者の発症状況、今後10年間の発症・有病件数の予測値などを調査・推計して、その結果を概略以下の内容でお届けいたします。

第1章 目次

第2章 イントロダクション

  • 概要
  • 近日刊行の関連調査

第3章 疫学

  • 疾患の背景
  • リスク要因と共存症
  • 世界的な傾向
    • 米国
    • 欧州主要5ヶ国
  • 予測手法
    • 利用した情報源
    • 利用しなかった情報源
    • 予測の前提条件と手法
  • 痛風の疫学予測(今後11年間分)
    • 診断を受けた発症者数
    • 診断を受けた有病者数
  • 議論
    • 疫学的な予測に関する結論
    • 分析の限界
    • 分析の強み

第4章 付録

図表一覧

目次
Product Code: GDHCER058

Gout is a type of inflammatory arthritis. The disease is triggered by the crystallization of uric acid within the joints and is associated with hyperuricemia, a condition in which the body either overproduces or under excretes uric acid. Attacks of gout are episodic in nature and although months may pass before the next attack occurs, the pain experienced during an attack can be debilitating. Men are at a higher risk for developing gout and the risk also increases with age, with a mean age at diagnosis for gout in both men and women of 61 years.

GlobalData epidemiologists forecast an increase in both the diagnosed incident cases and diagnosed prevalent cases of gout in the 6MM, from 1,374,065 diagnosed incident cases in 2013 to 1,649,065 diagnosed incident cases in 2023, at an annual growth rate (AGR) of 2.00%, and 13,750,047 diagnosed prevalent cases in 2013 to 17,625,944 diagnosed prevalent cases in 2023, at an AGR of 2.82%.

This forecast is supported by age- and sex-specific data obtained from country-specific estimates from peer reviewed journal articles, in which the study populations were representative of the general population in the respective markets. GlobalData epidemiologists used historical diagnosed incidence and diagnosed prevalence data which were available for Italy and the UK, along with linear regression methods to forecast the age- and sex-specific diagnosed incidence and diagnosed prevalence for Italy and the UK through 2023. The forecast provides the age- and sex-specific diagnosed incident cases and diagnosed prevalent cases of gout in each of the 6MM, with clinically relevant segmentations, which facilitate an in depth understanding of the emerging temporal trends, and informs strategies to improve the management of the disease. Additionally, GlobalData epidemiologists used the same methodology across the 6MM, which allows for a meaningful comparison of the forecast diagnosed incident cases and diagnosed prevalent cases of gout across these markets.

Scope

  • The Gout EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical epidemiological trends for gout in the six major markets (6MM) (US, France, Germany, Italy, Spain, and UK). In addition, this report includes a 10-year epidemiological forecast for the diagnosed incident cases and the diagnosed prevalent cases of gout segmented by sex and age (in five-year age groups beginning at 20 years and ending at =85 years). The diagnosed prevalent cases are then further segmented by the number of cases of gout flares and tophaceous gout.
  • The gout epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 6MM.

Reasons to buy

  • Develop business strategies by understanding the trends shaping and driving the global gout market.
  • Quantify patient populations in the global gout market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for gout therapeutics in each of the markets covered.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Upcoming Reports

3. Epidemiology

  • 3.1. Disease Background
  • 3.2. Risk Factors and Comorbidities
  • 3.3. Global Trends
    • 3.3.1. US
    • 3.3.2. 5EU
  • 3.4. Forecast Methodology
    • 3.4.1. Sources Used
    • 3.4.2. Sources Not Used
    • 3.4.3. Forecast Assumptions and Methods
  • 3.5. Epidemiological Forecast for Gout (2013-2023)
    • 3.5.1. Diagnosed Incidence
    • 3.5.2. Diagnosed Prevalence
  • 3.6. Discussion
    • 3.6.1. Epidemiological Forecast Insight
    • 3.6.2. Limitations of the Analysis
    • 3.6.3. Strengths of the Analysis

4. Appendix

  • 4.1. Bibliography
  • 4.2. About the Authors
    • 4.2.1. Epidemiologists
    • 4.2.2. Reviewers
    • 4.2.3. Global Director of Epidemiology
    • 4.2.4. Global Head of Healthcare
  • 4.3. About GlobalData
  • 4.4. About EpiCast
  • 4.5. Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbidities for Gout
  • Table 2: Summary of Reported Incidence and Prevalence of Gout in the 6MM*
  • Table 3: American College of Rheumatology Criteria for the Clinical Diagnosis of Gout
  • Table 4: Sources of Gout Incidence Data in 6MM
  • Table 5: Sources of Gout Prevalence Data in 6MM
  • Table 6: Sources of Gout Flare and Tophaceous Gout Data in 6MM
  • Table 7: 6MM, Sources Not Used in the Epidemiological Analysis of Gout
  • Table 8: 6MM, Diagnosed Incident Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 9: 6MM, Age-Specific Diagnosed Incident Cases of Gout, Both Sexes, N (Row %), 2013
  • Table 10: 6MM, Sex-Specific Diagnosed Incident Cases of Gout, Ages ≥20 Years, N (Row %), 2013
  • Table 11: 6MM, Diagnosed Prevalent Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Table 12: 6MM, Age-Specific Diagnosed Prevalent Cases of Gout, Both Sexes, N (Row %), 2013
  • Table 13: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gout, Ages ≥20 Years, N (Row %), 2013

List of Figures

  • Figure 1: 6MM, Diagnosed Incident Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 2: 6MM, Age-Specific Diagnosed Incident Cases of Gout, Both Sexes, N, 2013
  • Figure 3: 6MM, Sex-Specific Diagnosed Incident Cases of Gout, Ages ≥20 Years, N, 2013
  • Figure 4: 6MM, Age-Standardized Diagnosed Incidence of Gout (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013
  • Figure 5: 6MM, Diagnosed Prevalent Cases of Gout, Both Sexes, Ages ≥20 Years, N, 2013-2023
  • Figure 6: 6MM, Age-Specific Diagnosed Prevalent Cases of Gout, Both Sexes, N, 2013
  • Figure 7: 6MM, Sex-Specific Diagnosed Prevalent Cases of Gout, Ages ≥20 Years, N, 2013
  • Figure 8: 6MM, Age-Standardized Diagnosed Prevalence (%) of Gout, Ages ≥20 Years, by Sex, 2013
  • Figure 9: 6MM, Number of Gout Flares in the Diagnosed Prevalent Population of Gout, Both Sexes, Ages ≥20 Years, N, 2013 and 2023
  • Figure 10: 6MM, Tophaceous Gout Cases in the Diagnosed Prevalent Population of Gout, Both Sexes, Ages ≥20 Years, N, 2013 and 2023
Back to Top